Jerry Call

/Jerry Call

About Jerry Call

This author has not yet filled in any details.
So far Jerry Call has created 71 blog entries.

New Technology Developed Which Can Predict GIST Patient’s Response to Drugs with Amazing Accuracy

Researchers have developed a test that can accurately identify over 20% of GIST patients that are unlikely to respond to currently approved treatments. In addition, it can identify which patients need a higher dose [...]

By | 2018-10-29T13:42:22+00:00 June 29th, 2018|GIST Education, Mutational Testing, News, Newsletter|

Deciphera Pharmaceuticals Announces the Start of Phase 3 Clinical Trial with DCC-2618 in GIST

On January 4th, 2018 Deciphera Pharmaceuticals, Inc, announced the start of the Phase 3 INVICTUS trial. This randomized trial is for 4th line GIST patients that have failed (or are intolerant) the [...]

By | 2018-10-29T13:46:27+00:00 January 9th, 2018|Clinical Trials, News|

Why Do Cancer Patients Join Clinical Trials?

At the most basic level, cancer patients join clinical trials because of perceived value and perceived cost. In this context, perceived cost refers to more than just financial cost, although that is important. Perceived [...]

By | 2018-10-29T13:47:05+00:00 December 28th, 2017|Clinical Trials, News, Newsletter|

Clinical Registry Study Planned by ASCO

American Society of Clinical Oncology (ASCO) is planning its first-ever clinical registry study, the Targeted Agent and Profiling Utilization Registry (TAPUR).  ASCO plans should increase patient access to off-label drugs and match patients with [...]

By | 2018-07-06T13:59:34+00:00 January 6th, 2015|Gleevec, News, Patient Support, Side Effects, Stivarga, Sutent|

Recent Posts

Upcoming Events

  1. GDOL Los Angeles 2019

    February 16, 2019 @ 8:00 AM - 5:00 PM